Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.

Steins A, Ebbing EA, Creemers A, van der Zalm AP, Jibodh RA, Waasdorp C, Meijer SL, van Delden OM, Krishnadath KK, Hulshof MCCM, Bennink RJ, Punt CJA, Medema JP, Bijlsma MF, van Laarhoven HWM.

Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32364. [Epub ahead of print]

PMID:
31018252
2.

Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma.

Ebbing EA, van der Zalm AP, Steins A, Creemers A, Hermsen S, Rentenaar R, Klein M, Waasdorp C, Hooijer GKJ, Meijer SL, Krishnadath KK, Punt CJA, van Berge Henegouwen MI, Gisbertz SS, van Delden OM, Hulshof MCCM, Medema JP, van Laarhoven HWM, Bijlsma MF.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2237-2242. doi: 10.1073/pnas.1820459116. Epub 2019 Jan 22.

3.

Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer.

van der Bogt RD, Noordman BJ, Krishnadath KK, Roumans CAM, Schoon EJ, Oostenbrug LE, Siersema PD, Vleggaar FP, van Lanschot JJB, Spaander MCW.

Endoscopy. 2019 Apr;51(4):326-332. doi: 10.1055/a-0795-3220. Epub 2018 Nov 29.

PMID:
30497088
4.

Genomic profiles of primary and metastatic esophageal adenocarcinoma identified via digital sorting of pure cell populations: results from a case report.

Isidori F, Malvi D, Fittipaldi S, Forcato C, Bozzarelli I, Sala C, Raulli G, D'Errico A, Fiorentino M, Seri M, Krishnadath KK, Bonora E, Mattioli S; EAC-BAGH group.

BMC Cancer. 2018 Sep 12;18(1):889. doi: 10.1186/s12885-018-4789-4.

5.

Smokeless Tobacco and Cigar and/or Pipe Are Risk Factors for Barrett Esophagus in Male Patients With Gastroesophageal Reflux Disease.

Westra WM, Lutzke LS, Mostafavi NS, Roes AL, Calpe S, Wang KK, Krishnadath KK.

Mayo Clin Proc. 2018 Sep;93(9):1282-1289. doi: 10.1016/j.mayocp.2018.04.022.

PMID:
30193675
6.

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas.

Creemers A, Ebbing EA, Pelgrim TC, Lagarde SM, van Etten-Jamaludin FS, van Berge Henegouwen MI, Hulshof MCCM, Krishnadath KK, Meijer SL, Bijlsma MF, van Oijen MGH, van Laarhoven HWM.

Sci Rep. 2018 Sep 5;8(1):13281. doi: 10.1038/s41598-018-31548-6.

7.

TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact.

Braunschmid T, Kührer I, Mittlböck M, Westerhoff M, Kappel-Latif S, Brammen L, Krishnadath KK, Phillips WA, Gnant M, Kandioler D.

Ann N Y Acad Sci. 2018 Dec;1434(1):46-53. doi: 10.1111/nyas.13947. Epub 2018 Aug 15.

PMID:
30112858
8.

Preclinical models for the study of Barrett's carcinogenesis.

Read MD, Krishnadath KK, Clemons NJ, Phillips WA.

Ann N Y Acad Sci. 2018 Dec;1434(1):139-148. doi: 10.1111/nyas.13916. Epub 2018 Jul 5. Review.

PMID:
29974961
9.

The dynamics of HER2 status in esophageal adenocarcinoma.

Creemers A, Ebbing EA, Hooijer GKJ, Stap L, Jibodh-Mulder RA, Gisbertz SS, van Berge Henegouwen MI, van Montfoort ML, Hulshof MCCM, Krishnadath KK, van Oijen MGH, Bijlsma MF, Meijer SL, van Laarhoven HWM.

Oncotarget. 2018 Jun 1;9(42):26787-26799. doi: 10.18632/oncotarget.25507. eCollection 2018 Jun 1.

10.

microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients.

Mari L, Hoefnagel SJM, Zito D, van de Meent M, van Endert P, Calpe S, Sancho Serra MDC, Heemskerk MHM, van Laarhoven HWM, Hulshof MCCM, Gisbertz SS, Medema JP, van Berge Henegouwen MI, Meijer SL, Bergman JJGHM, Milano F, Krishnadath KK.

Gastroenterology. 2018 Sep;155(3):784-798. doi: 10.1053/j.gastro.2018.06.030. Epub 2018 Jun 7.

PMID:
29885883
11.

The Amsterdam ReBus progressor cohort: identification of 165 Barrett's surveillance patients who progressed to early neoplasia and 723 nonprogressor patients.

Duits LC, Klaver E, Bureo Gonzalez A, Boerwinkel DF, Ten Kate FJW, Offerhaus GJA, Meijer SL, Visser M, Seldenrijk CA, Krishnadath KK, Schoon EJ, Weusten BLAM, Mallant-Hent RC, Pouw RE, Bergman JJGHM.

Dis Esophagus. 2018 Jun 4. doi: 10.1093/dote/doy037. [Epub ahead of print]

PMID:
29873685
12.

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.

Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB; SANO study group.

Lancet Oncol. 2018 Jul;19(7):965-974. doi: 10.1016/S1470-2045(18)30201-8. Epub 2018 Jun 1.

PMID:
29861116
13.

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.

Steins A, Ebbing EA, Pistorius MCM, Waasdorp C, Krishnadath KK, Medema JP, Wilmink JW, Mathôt RAA, Bijlsma MF, van Laarhoven HWM.

Drug Deliv. 2017 Nov;24(1):1801-1810. doi: 10.1080/10717544.2017.1406559.

PMID:
29172757
14.

Esophageal sensitivity to acid in patients with Barrett's esophagus is not related to preserved esophageal mucosal integrity.

Weijenborg PW, Smout AJPM, Krishnadath KK, Bergman JGHM, Verheij J, Bredenoord AJ.

Neurogastroenterol Motil. 2017 Jul;29(7). doi: 10.1111/nmo.13066. Epub 2017 Mar 30.

PMID:
28370911
15.

Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.

Ebbing EA, Steins A, Fessler E, Stathi P, Lesterhuis WJ, Krishnadath KK, Vermeulen L, Medema JP, Bijlsma MF, van Laarhoven HWM.

Gastroenterology. 2017 Jul;153(1):63-76.e14. doi: 10.1053/j.gastro.2017.03.004. Epub 2017 Mar 9.

PMID:
28286209
16.

Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.

Duits LC, van der Wel MJ, Cotton CC, Phoa KN, Ten Kate FJW, Seldenrijk CA, Offerhaus GJA, Visser M, Meijer SL, Mallant-Hent RC, Krishnadath KK, Pouw RE, Tijssen JGP, Shaheen NJ, Bergman JJGHM.

Gastroenterology. 2017 Apr;152(5):993-1001.e1. doi: 10.1053/j.gastro.2016.12.008. Epub 2016 Dec 22.

PMID:
28012849
17.

Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasis.

Liu DS, Hoefnagel SJ, Fisher OM, Krishnadath KK, Montgomery KG, Busuttil RA, Colebatch AJ, Read M, Duong CP, Phillips WA, Clemons NJ.

Oncotarget. 2016 Dec 13;7(50):83342-83358. doi: 10.18632/oncotarget.13391.

18.

Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus.

Martinez P, Timmer MR, Lau CT, Calpe S, Sancho-Serra Mdel C, Straub D, Baker AM, Meijer SL, Kate FJ, Mallant-Hent RC, Naber AH, van Oijen AH, Baak LC, Scholten P, Böhmer CJ, Fockens P, Bergman JJ, Maley CC, Graham TA, Krishnadath KK.

Nat Commun. 2016 Aug 19;7:12158. doi: 10.1038/ncomms12158.

19.

Genetic Abnormalities in Biliary Brush Samples for Distinguishing Cholangiocarcinoma from Benign Strictures in Primary Sclerosing Cholangitis.

Timmer MR, Lau CT, Meijer SL, Fockens P, Rauws EA, Ponsioen CY, Calpe S, Krishnadath KK.

Gastroenterol Res Pract. 2016;2016:4381513. doi: 10.1155/2016/4381513. Epub 2016 Apr 3.

20.

Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors.

Calpe S, Correia AC, Sancho-Serra Mdel C, Krishnadath KK.

MAbs. 2016 May-Jun;8(4):678-88. doi: 10.1080/19420862.2016.1158380.

21.

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.

Ebbing EA, Medema JP, Damhofer H, Meijer SL, Krishnadath KK, van Berge Henegouwen MI, Bijlsma MF, van Laarhoven HW.

Oncotarget. 2016 Mar 1;7(9):10243-54. doi: 10.18632/oncotarget.7200.

22.

Effective Inhibition of Bone Morphogenetic Protein Function by Highly Specific Llama-Derived Antibodies.

Calpe S, Wagner K, El Khattabi M, Rutten L, Zimberlin C, Dolk E, Verrips CT, Medema JP, Spits H, Krishnadath KK.

Mol Cancer Ther. 2015 Nov;14(11):2527-40. doi: 10.1158/1535-7163.MCT-14-0956. Epub 2015 Sep 8.

23.

Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.

Varghese S, Newton R, Ross-Innes CS, Lao-Sirieix P, Krishnadath KK, O'Donovan M, Novelli M, Wernisch L, Bergman J, Fitzgerald RC.

Gastroenterology. 2015 Nov;149(6):1511-1518.e5. doi: 10.1053/j.gastro.2015.07.053. Epub 2015 Aug 3.

PMID:
26248086
24.

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol.

Noordman BJ, Shapiro J, Spaander MC, Krishnadath KK, van Laarhoven HW, van Berge Henegouwen MI, Nieuwenhuijzen GA, van Hillegersberg R, Sosef MN, Steyerberg EW, Wijnhoven BP, van Lanschot JJ; SANO study group.

JMIR Res Protoc. 2015 Jun 29;4(2):e79. doi: 10.2196/resprot.4320.

25.

Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study.

Timmer MR, Martinez P, Lau CT, Westra WM, Calpe S, Rygiel AM, Rosmolen WD, Meijer SL, Ten Kate FJ, Dijkgraaf MG, Mallant-Hent RC, Naber AH, van Oijen AH, Baak LC, Scholten P, Böhmer CJ, Fockens P, Maley CC, Graham TA, Bergman JJ, Krishnadath KK.

Gut. 2016 Oct;65(10):1602-10. doi: 10.1136/gutjnl-2015-309642. Epub 2015 Jun 23.

26.

Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma.

Davelaar AL, Straub D, Parikh KB, Lau L, Fockens P, Krishnadath KK.

Int J Oncol. 2015 Aug;47(2):583-91. doi: 10.3892/ijo.2015.3040. Epub 2015 Jun 9.

PMID:
26058606
27.

Molecular pathogenesis of Barrett esophagus: current evidence.

Krishnadath KK, Wang KK.

Gastroenterol Clin North Am. 2015 Jun;44(2):233-47. doi: 10.1016/j.gtc.2015.02.002. Epub 2015 Mar 29. Review.

PMID:
26021192
28.

Vitamin D Receptor Polymorphisms Are Associated with Reduced Esophageal Vitamin D Receptor Expression and Reduced Esophageal Adenocarcinoma Risk.

Janmaat VT, Van De Winkel A, Peppelenbosch MP, Spaander MC, Uitterlinden AG, Pourfarzad F, Tilanus HW, Rygiel AM, Moons LM, Arp PP, Krishnadath KK, Kuipers EJ, Van Der Laan LJ.

Mol Med. 2015 Apr 21;21:346-54. doi: 10.2119/molmed.2012.00336.

29.

Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract.

Damhofer H, Ebbing EA, Steins A, Welling L, Tol JA, Krishnadath KK, van Leusden T, van de Vijver MJ, Besselink MG, Busch OR, van Berge Henegouwen MI, van Delden O, Meijer SL, Dijk F, Medema JP, van Laarhoven HW, Bijlsma MF.

J Transl Med. 2015 Apr 11;13:115. doi: 10.1186/s12967-015-0469-1.

30.

Active matrix metalloproteases are expressed early on and are high during the Barrett's esophagus malignancy sequence.

Davelaar AL, Straub D, Buttar NS, Fockens P, Krishnadath KK.

Scand J Gastroenterol. 2015 Mar;50(3):321-32. doi: 10.3109/00365521.2014.940379. Epub 2015 Jan 6.

PMID:
25562781
31.

MicroRNA Expression can be a Promising Strategy for the Detection of Barrett's Esophagus: A Pilot Study.

Bansal A, Hong X, Lee IH, Krishnadath KK, Mathur SC, Gunewardena S, Rastogi A, Sharma P, Christenson LK.

Clin Transl Gastroenterol. 2014 Dec 11;5:e65. doi: 10.1038/ctg.2014.17.

32.

Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: a prospective follow-up study.

Davelaar AL, Calpe S, Lau L, Timmer MR, Visser M, Ten Kate FJ, Parikh KB, Meijer SL, Bergman JJ, Fockens P, Krishnadath KK.

Genes Chromosomes Cancer. 2015 Feb;54(2):82-90. doi: 10.1002/gcc.22220. Epub 2014 Oct 4.

PMID:
25284618
33.

Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers.

Timmer MR, Brankley SM, Gorospe EC, Sun G, Lutzke LS, Iyer PG, Halling KC, Krishnadath KK, Wang KK.

Gastrointest Endosc. 2014 Dec;80(6):984-91. doi: 10.1016/j.gie.2014.06.023. Epub 2014 Jul 29.

34.

Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.

Duits LC, Phoa KN, Curvers WL, Ten Kate FJ, Meijer GA, Seldenrijk CA, Offerhaus GJ, Visser M, Meijer SL, Krishnadath KK, Tijssen JG, Mallant-Hent RC, Bergman JJ.

Gut. 2015 May;64(5):700-6. doi: 10.1136/gutjnl-2014-307278. Epub 2014 Jul 17.

PMID:
25034523
35.

A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia.

Mari L, Milano F, Parikh K, Straub D, Everts V, Hoeben KK, Fockens P, Buttar NS, Krishnadath KK.

Cell Rep. 2014 May 22;7(4):1197-210. doi: 10.1016/j.celrep.2014.03.074. Epub 2014 May 1.

36.

Suppression of p21Rac signaling and increased innate immunity mediate remission in Crohn's disease.

Parikh K, Zhou L, Somasundaram R, Fuhler GM, Deuring JJ, Blokzijl T, Regeling A, Kuipers EJ, Weersma RK, Nuij VJ, Alves M, Vogelaar L, Visser L, de Haar C, Krishnadath KK, van der Woude CJ, Dijkstra G, Faber KN, Peppelenbosch MP.

Sci Transl Med. 2014 Apr 23;6(233):233ra53. doi: 10.1126/scitranslmed.3006763.

37.

Electroporation of dendritic cells with autologous total RNA from tumor material.

Milano F, Krishnadath KK.

Methods Mol Biol. 2014;1139:87-95. doi: 10.1007/978-1-4939-0345-0_9.

PMID:
24619673
38.

Barrett's esophagus: cancer and molecular biology.

Gibson MK, Dhaliwal AS, Clemons NJ, Phillips WA, Dvorak K, Tong D, Law S, Pirchi ED, Räsänen J, Krasna MJ, Parikh K, Krishnadath KK, Chen Y, Griffiths L, Colleypriest BJ, Farrant JM, Tosh D, Das KM, Bajpai M.

Ann N Y Acad Sci. 2013 Oct;1300:296-314. doi: 10.1111/nyas.12252. Review.

PMID:
24117650
39.

Nano-curcumin inhibits proliferation of esophageal adenocarcinoma cells and enhances the T cell mediated immune response.

Milano F, Mari L, van de Luijtgaarden W, Parikh K, Calpe S, Krishnadath KK.

Front Oncol. 2013 May 29;3:137. doi: 10.3389/fonc.2013.00137. eCollection 2013.

40.

Genetic and epigenetic abnormalities in primary sclerosing cholangitis-associated cholangiocarcinoma.

Timmer MR, Beuers U, Fockens P, Ponsioen CY, Rauws EA, Wang KK, Krishnadath KK.

Inflamm Bowel Dis. 2013 Jul;19(8):1789-97. doi: 10.1097/MIB.0b013e318281f49a. Review.

PMID:
23615529
41.

Predictive biomarkers for Barrett's esophagus: so near and yet so far.

Timmer MR, Sun G, Gorospe EC, Leggett CL, Lutzke L, Krishnadath KK, Wang KK.

Dis Esophagus. 2013 Aug;26(6):574-81. doi: 10.1111/dote.12015. Epub 2013 Jan 14. Review.

42.

Activation of the BMP4 pathway and early expression of CDX2 characterize non-specialized columnar metaplasia in a human model of Barrett's esophagus.

Castillo D, Puig S, Iglesias M, Seoane A, de Bolós C, Munitiz V, Parrilla P, Comerma L, Poulsom R, Krishnadath KK, Grande L, Pera M.

J Gastrointest Surg. 2012 Feb;16(2):227-37; discussion 237. doi: 10.1007/s11605-011-1758-5. Epub 2011 Nov 11.

PMID:
22076569
43.

Molecular mechanisms of Barrett's esophagus and adenocarcinoma.

Dvorak K, Goldman A, Kong J, Lynch JP, Hutchinson L, Houghton JM, Chen H, Chen X, Krishnadath KK, Westra WM.

Ann N Y Acad Sci. 2011 Sep;1232:381-91. doi: 10.1111/j.1749-6632.2011.06062.x.

PMID:
21950830
44.

Barrett's esophagus: genetic and cell changes.

Souza RF, Freschi G, Taddei A, Ringressi MN, Bechi P, Castiglione F, Rossi Degl'Innocenti D, Triadafilopoulos G, Wang JS, Chang AC, Barr H, Bajpai M, Das KM, Schneider PM, Krishnadath KK, Malhotra U, Lynch JP.

Ann N Y Acad Sci. 2011 Sep;1232:18-35. doi: 10.1111/j.1749-6632.2011.06043.x. Review.

PMID:
21950805
45.

Do we still need EUS in the workup of patients with early esophageal neoplasia? A retrospective analysis of 131 cases.

Pouw RE, Heldoorn N, Alvarez Herrero L, ten Kate FJ, Visser M, Busch OR, van Berge Henegouwen MI, Krishnadath KK, Weusten BL, Fockens P, Bergman JJ.

Gastrointest Endosc. 2011 Apr;73(4):662-8. doi: 10.1016/j.gie.2010.10.046. Epub 2011 Jan 26.

PMID:
21272876
46.

Reproducibility of protein identification of selected cell types in Barrett's esophagus analyzed by combining laser-capture microdissection and mass spectrometry.

Stingl C, van Vilsteren FG, Guzel C, Ten Kate FJ, Visser M, Krishnadath KK, Bergman JJ, Luider TM.

J Proteome Res. 2011 Jan 7;10(1):288-98. doi: 10.1021/pr100709b. Epub 2010 Dec 3.

PMID:
21053923
47.

A reappraisal of brush cytology for screening of Barrett's esophagus.

Pacha AF, Krishnadath KK.

Endoscopy. 2010 Oct;42(10):864-5. doi: 10.1055/s-0030-1255757. Epub 2010 Sep 30. No abstract available.

PMID:
20886406
48.

Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.

Milano F, Guarriera M, Rygiel AM, Krishnadath KK.

PLoS One. 2010 Aug 26;5(8):e12424. doi: 10.1371/journal.pone.0012424.

49.

Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.

Rygiel AM, Milano F, Ten Kate FJ, Bergman JJ, Krishnadath KK.

J Oncol. 2010;2010:382582. doi: 10.1155/2010/382582. Epub 2010 Jun 9.

50.

Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated.

Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, Bohmer C, Mallant-Hent RC, van Oijen A, Naber AH, Scholten P, Busch OR, Blaauwgeers HG, Meijer GA, Bergman JJ.

Am J Gastroenterol. 2010 Jul;105(7):1523-30. doi: 10.1038/ajg.2010.171. Epub 2010 May 11.

PMID:
20461069

Supplemental Content

Loading ...
Support Center